Bharat Immunologicals & Biologicals Corp. Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2015. For the quarter, the company reported net salesincome from operations (net off excise duty) of INR 134.121 million compared to INR 248.301 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 40.527 million compared to INR 12.237 million a year ago. Loss from ordinary activates before tax was INR 38.480 million compared to INR 12.019 million a year ago. Net loss was INR 24.765 million or INR 0.57 per basic and diluted share before and after extraordinary items (not annualized) compared to INR 8.370 million or INR 0.19 per basic and diluted share before and after extraordinary items (not annualized) a year ago.

For the nine months period, the company reported net salesincome from operations (net off excise duty) of INR 299.910 million compared to INR 1,462.163 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 85.826 million compared to profit from operations before other income, finance costs and exceptional items of INR 65.219 million a year ago. Loss from ordinary activates before tax was INR 79.127 million compared to profit from ordinary activates before tax of INR 27.694 million a year ago. Net loss was INR 56.251 million or INR 1.30 per basic and diluted share before and after extraordinary items (not annualized) compared to net profit of INR 23.033 million or INR 0.53 per basic and diluted share before and after extraordinary items (not annualized) a year ago.